{"id":380487,"date":"2020-11-12T17:33:12","date_gmt":"2020-11-12T22:33:12","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=380487"},"modified":"2020-11-12T17:33:12","modified_gmt":"2020-11-12T22:33:12","slug":"plx-pharma-inc-2020-third-quarter-financial-results-and-business-update-conference-call-rescheduled-to-november-16-2020","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/plx-pharma-inc-2020-third-quarter-financial-results-and-business-update-conference-call-rescheduled-to-november-16-2020\/","title":{"rendered":"PLx Pharma Inc. 2020 Third Quarter Financial Results and Business Update Conference Call Rescheduled to November 16, 2020"},"content":{"rendered":"<div class=\"mw_release\">\n<p>SPARTA, N.J., Nov.  12, 2020  (GLOBE NEWSWIRE) &#8212; PLx Pharma Inc. (NASDAQ: PLXP) (\u201cPLx\u201d or the \u201cCompany\u201d), a late-stage specialty pharmaceutical company focused on developing its clinically-validated and patent-protected PLxGuard\u2122 delivery system to provide more effective and safer products, VAZALORE\u2122 325 mg and VAZALORE\u2122 81 mg (referred to together as \u201cVAZALORE\u201d\u2122), announced today that the Company has rescheduled its 2020 third quarter financial results call to Monday, November 16, 2020.<\/p>\n<p>Natasha Giordano, President and Chief Executive Officer, and Rita O\u2019Connor, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows:<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:30%;width:30%;min-width:30%;vertical-align: top\">Date<\/td>\n<td style=\"max-width:70%;width:70%;min-width:70%;vertical-align: top\">Monday, November 16, 2020<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">Time<\/td>\n<td style=\"vertical-align: top\">4:30 p.m. ET<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">Toll free (U.S.)<\/td>\n<td style=\"vertical-align: top\">(866) 394-2901<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">International<br \/>Conference ID<\/td>\n<td style=\"vertical-align: top\">(616) 548-5567<br \/>2219797<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">Webcast (live and replay)<\/td>\n<td style=\"vertical-align: top\">\n            <a href=\"http:\/\/www.plxpharma.com\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.plxpharma.com<\/a> under the \u2018Investor Relations\u2019 section.<\/td>\n<\/tr>\n<\/table>\n<p>A replay of the conference call will be available for two weeks after the call&#8217;s completion by dialing (855) 859-2056 (U.S.) or (404) 537-3406 (International). The conference ID for the replay is 2219797. The archived webcast will be available for 30 days via the aforementioned URL.<\/p>\n<p>\n        <strong>About VAZALORE<\/strong>\n      <\/p>\n<p>VAZALORE 325 mg is an FDA-approved liquid-filled aspirin capsule that provides patients with vascular disease and diabetic patients who are candidates for aspirin therapy with faster, reliable and more predictable platelet inhibition as compared to enteric-coated aspirin, while also reducing the risk of stomach erosions and ulcers, as compared to immediate-release aspirin, common in an acute setting. PLx is focused on collecting the data, including results from a bioequivalence study, required for post-approval manufacturing changes, which will be included in the sNDA filing for VAZALORE 325 mg and to support approval of low dose VAZALORE 81 mg.<\/p>\n<p>\n        <strong>About\u00a0PLx Pharma Inc.<\/strong><br \/>\n        <br \/>PLx Pharma Inc. is a late-stage specialty pharmaceutical company focused on developing its clinically validated and patent-protected PLxGuard\u2122 delivery system to provide more effective and safer products. The PLxGuard delivery system works by targeting delivery of active pharmaceutical ingredients to various portions of the gastrointestinal (GI) tract. PLx believes this has the potential to improve the absorption of many drugs currently on the market or in development, and to reduce the risk of stomach erosions and ulcers associated with aspirin and ibuprofen, and potentially other drugs.<\/p>\n<p>To learn more about\u00a0PLx Pharma Inc. and its pipeline, please\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WV3NRFgnUzp5NGqru8uactFJTqV4Iqmco3-X7Lt-vFEWEME_AK8hjey6rODhePbL6kA7GC8Gj08ZkJKArM-WTNtn0Rb7b-FJsaPJhRkqZKY=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">visit www.plxpharma.com<\/a>.<\/p>\n<p>\n        <strong>Contact <\/strong><br \/>\n        <br \/>Investor Relations:<br \/>Lisa M. Wilson, In-Site Communications, Inc.<br \/>T: 212-452-2793<br \/>E: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=No3K0MqQw7WScGUDzpUzmSP4YTL1lLy29IamWw5HXxnUebd6-EealyFnVKkGytqjVCk2YpMQaCEaT3Dq9_6woV94xETacPyqExayP5f_ZkQ=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">lwilson@insitecony.com<\/a><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTM4NSMzODI1MzMyIzIwMjAyMjU=\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SPARTA, N.J., Nov. 12, 2020 (GLOBE NEWSWIRE) &#8212; PLx Pharma Inc. (NASDAQ: PLXP) (\u201cPLx\u201d or the \u201cCompany\u201d), a late-stage specialty pharmaceutical company focused on developing its clinically-validated and patent-protected PLxGuard\u2122 delivery system to provide more effective and safer products, VAZALORE\u2122 325 mg and VAZALORE\u2122 81 mg (referred to together as \u201cVAZALORE\u201d\u2122), announced today that the Company has rescheduled its 2020 third quarter financial results call to Monday, November 16, 2020. Natasha Giordano, President and Chief Executive Officer, and Rita O\u2019Connor, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows: Date Monday, November 16, 2020 Time 4:30 p.m. ET Toll free (U.S.) (866) 394-2901 InternationalConference ID (616) 548-55672219797 Webcast (live and &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/plx-pharma-inc-2020-third-quarter-financial-results-and-business-update-conference-call-rescheduled-to-november-16-2020\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;PLx Pharma Inc. 2020 Third Quarter Financial Results and Business Update Conference Call Rescheduled to November 16, 2020&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-380487","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>PLx Pharma Inc. 2020 Third Quarter Financial Results and Business Update Conference Call Rescheduled to November 16, 2020 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/plx-pharma-inc-2020-third-quarter-financial-results-and-business-update-conference-call-rescheduled-to-november-16-2020\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PLx Pharma Inc. 2020 Third Quarter Financial Results and Business Update Conference Call Rescheduled to November 16, 2020 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SPARTA, N.J., Nov. 12, 2020 (GLOBE NEWSWIRE) &#8212; PLx Pharma Inc. (NASDAQ: PLXP) (\u201cPLx\u201d or the \u201cCompany\u201d), a late-stage specialty pharmaceutical company focused on developing its clinically-validated and patent-protected PLxGuard\u2122 delivery system to provide more effective and safer products, VAZALORE\u2122 325 mg and VAZALORE\u2122 81 mg (referred to together as \u201cVAZALORE\u201d\u2122), announced today that the Company has rescheduled its 2020 third quarter financial results call to Monday, November 16, 2020. Natasha Giordano, President and Chief Executive Officer, and Rita O\u2019Connor, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows: Date Monday, November 16, 2020 Time 4:30 p.m. ET Toll free (U.S.) (866) 394-2901 InternationalConference ID (616) 548-55672219797 Webcast (live and &hellip; Continue reading &quot;PLx Pharma Inc. 2020 Third Quarter Financial Results and Business Update Conference Call Rescheduled to November 16, 2020&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/plx-pharma-inc-2020-third-quarter-financial-results-and-business-update-conference-call-rescheduled-to-november-16-2020\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-12T22:33:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTM4NSMzODI1MzMyIzIwMjAyMjU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plx-pharma-inc-2020-third-quarter-financial-results-and-business-update-conference-call-rescheduled-to-november-16-2020\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plx-pharma-inc-2020-third-quarter-financial-results-and-business-update-conference-call-rescheduled-to-november-16-2020\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"PLx Pharma Inc. 2020 Third Quarter Financial Results and Business Update Conference Call Rescheduled to November 16, 2020\",\"datePublished\":\"2020-11-12T22:33:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plx-pharma-inc-2020-third-quarter-financial-results-and-business-update-conference-call-rescheduled-to-november-16-2020\\\/\"},\"wordCount\":396,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plx-pharma-inc-2020-third-quarter-financial-results-and-business-update-conference-call-rescheduled-to-november-16-2020\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NTM4NSMzODI1MzMyIzIwMjAyMjU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plx-pharma-inc-2020-third-quarter-financial-results-and-business-update-conference-call-rescheduled-to-november-16-2020\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plx-pharma-inc-2020-third-quarter-financial-results-and-business-update-conference-call-rescheduled-to-november-16-2020\\\/\",\"name\":\"PLx Pharma Inc. 2020 Third Quarter Financial Results and Business Update Conference Call Rescheduled to November 16, 2020 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plx-pharma-inc-2020-third-quarter-financial-results-and-business-update-conference-call-rescheduled-to-november-16-2020\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plx-pharma-inc-2020-third-quarter-financial-results-and-business-update-conference-call-rescheduled-to-november-16-2020\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NTM4NSMzODI1MzMyIzIwMjAyMjU=\",\"datePublished\":\"2020-11-12T22:33:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plx-pharma-inc-2020-third-quarter-financial-results-and-business-update-conference-call-rescheduled-to-november-16-2020\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plx-pharma-inc-2020-third-quarter-financial-results-and-business-update-conference-call-rescheduled-to-november-16-2020\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plx-pharma-inc-2020-third-quarter-financial-results-and-business-update-conference-call-rescheduled-to-november-16-2020\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NTM4NSMzODI1MzMyIzIwMjAyMjU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NTM4NSMzODI1MzMyIzIwMjAyMjU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plx-pharma-inc-2020-third-quarter-financial-results-and-business-update-conference-call-rescheduled-to-november-16-2020\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PLx Pharma Inc. 2020 Third Quarter Financial Results and Business Update Conference Call Rescheduled to November 16, 2020\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PLx Pharma Inc. 2020 Third Quarter Financial Results and Business Update Conference Call Rescheduled to November 16, 2020 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/plx-pharma-inc-2020-third-quarter-financial-results-and-business-update-conference-call-rescheduled-to-november-16-2020\/","og_locale":"en_US","og_type":"article","og_title":"PLx Pharma Inc. 2020 Third Quarter Financial Results and Business Update Conference Call Rescheduled to November 16, 2020 - Market Newsdesk","og_description":"SPARTA, N.J., Nov. 12, 2020 (GLOBE NEWSWIRE) &#8212; PLx Pharma Inc. (NASDAQ: PLXP) (\u201cPLx\u201d or the \u201cCompany\u201d), a late-stage specialty pharmaceutical company focused on developing its clinically-validated and patent-protected PLxGuard\u2122 delivery system to provide more effective and safer products, VAZALORE\u2122 325 mg and VAZALORE\u2122 81 mg (referred to together as \u201cVAZALORE\u201d\u2122), announced today that the Company has rescheduled its 2020 third quarter financial results call to Monday, November 16, 2020. Natasha Giordano, President and Chief Executive Officer, and Rita O\u2019Connor, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows: Date Monday, November 16, 2020 Time 4:30 p.m. ET Toll free (U.S.) (866) 394-2901 InternationalConference ID (616) 548-55672219797 Webcast (live and &hellip; Continue reading \"PLx Pharma Inc. 2020 Third Quarter Financial Results and Business Update Conference Call Rescheduled to November 16, 2020\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/plx-pharma-inc-2020-third-quarter-financial-results-and-business-update-conference-call-rescheduled-to-november-16-2020\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-12T22:33:12+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTM4NSMzODI1MzMyIzIwMjAyMjU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plx-pharma-inc-2020-third-quarter-financial-results-and-business-update-conference-call-rescheduled-to-november-16-2020\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plx-pharma-inc-2020-third-quarter-financial-results-and-business-update-conference-call-rescheduled-to-november-16-2020\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"PLx Pharma Inc. 2020 Third Quarter Financial Results and Business Update Conference Call Rescheduled to November 16, 2020","datePublished":"2020-11-12T22:33:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plx-pharma-inc-2020-third-quarter-financial-results-and-business-update-conference-call-rescheduled-to-november-16-2020\/"},"wordCount":396,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plx-pharma-inc-2020-third-quarter-financial-results-and-business-update-conference-call-rescheduled-to-november-16-2020\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTM4NSMzODI1MzMyIzIwMjAyMjU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plx-pharma-inc-2020-third-quarter-financial-results-and-business-update-conference-call-rescheduled-to-november-16-2020\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/plx-pharma-inc-2020-third-quarter-financial-results-and-business-update-conference-call-rescheduled-to-november-16-2020\/","name":"PLx Pharma Inc. 2020 Third Quarter Financial Results and Business Update Conference Call Rescheduled to November 16, 2020 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plx-pharma-inc-2020-third-quarter-financial-results-and-business-update-conference-call-rescheduled-to-november-16-2020\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plx-pharma-inc-2020-third-quarter-financial-results-and-business-update-conference-call-rescheduled-to-november-16-2020\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTM4NSMzODI1MzMyIzIwMjAyMjU=","datePublished":"2020-11-12T22:33:12+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plx-pharma-inc-2020-third-quarter-financial-results-and-business-update-conference-call-rescheduled-to-november-16-2020\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/plx-pharma-inc-2020-third-quarter-financial-results-and-business-update-conference-call-rescheduled-to-november-16-2020\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plx-pharma-inc-2020-third-quarter-financial-results-and-business-update-conference-call-rescheduled-to-november-16-2020\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTM4NSMzODI1MzMyIzIwMjAyMjU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTM4NSMzODI1MzMyIzIwMjAyMjU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plx-pharma-inc-2020-third-quarter-financial-results-and-business-update-conference-call-rescheduled-to-november-16-2020\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"PLx Pharma Inc. 2020 Third Quarter Financial Results and Business Update Conference Call Rescheduled to November 16, 2020"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/380487","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=380487"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/380487\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=380487"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=380487"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=380487"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}